Physician Assistant Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Allison Mitchell

Physician Assistant Roanoke, VA Physician Assistant

NPI 1881957173 CMS profile 10962941

2762 Electric Rd Ste A, Roanoke, VA 24018

Open in the dashboard

General payments

$2,670

158 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Allison Mitchell of Roanoke, VA is reported in the CMS Open Payments database as having received $2,670 across 158 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $24 1
2023 General $912 49
2022 General $1,051 64
2021 General $684 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Allison Mitchell
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Allison Mitchell were reported at $0. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Allison Mitchell Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $684 $132 $37–$438 $132
2022 $1,051 $155 $48–$522 $149
2023 $912 $167 $52–$557 $160
2024 $24 $178 $55–$600 $164
2025 $0 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Amgen Inc. $497 27 payments
  2. Novartis Pharmaceuticals Corporation $437 23 payments
  3. E.R. Squibb & Sons, L.L.C. $397 32 payments
  4. Pfizer Inc. $234 16 payments
  5. Janssen Pharmaceuticals, Inc $234 14 payments
  6. Merck Sharp & Dohme Corporation $185 10 payments
  7. AstraZeneca Pharmaceuticals LP $109 6 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $103 7 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $95 5 payments
  10. Esperion Therapeutics, Inc. $64 3 payments
  11. Other $315 15 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $2,670 158 payments
Products named General payments · program years 2021–2024
  1. Repatha $497 27 payments
  2. ELIQUIS Cardiovascular $271 24 payments
  3. XARELTO $234 14 payments
  4. PAXLOVID $179 12 payments
  5. LEQVIO Cardiovascular $170 8 payments
  6. VERQUVO Cardiovascular $170 9 payments
  7. ELIQUIS Cardiovascular;Metabolic Disease $165 11 payments
  8. LEQVIO Cardiology/Vascular Diseases $160 9 payments
  9. VERQUVO Cardiovascular $113 6 payments
  10. CAMZYOS $104 7 payments
  11. Other $1,014 56 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

1,045

Median for Physician Assistant: 241

Drug cost

$235,708

Median for Physician Assistant: $4,110

Branded share of claims

35.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 173 $170,139
Entresto Sacubitril/Valsartan Brand 36 $31,970
Xarelto Rivaroxaban Brand 29 $25,460
Ranolazine Er Ranolazine Brand 11 $1,045
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 24 $1,000
Metoprolol Succinate Generic 93 $643
Rosuvastatin Calcium Generic 43 $626
Losartan Potassium Generic 62 $571
Ezetimibe Generic 20 $543
Atorvastatin Calcium Generic 93 $510

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $24
$24 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

158 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record